Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | ATM | Q13315 | 2/20 | 0.45 |
| ▸ | TSHR | P16473 | 6/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 2/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.41 |
| ▸ | ESR1 | P03372 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.41 |
| ▸ | RNASEL | Q05823 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.40 |
| ▸ | NAAA | Q02083 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5201584 | 0.92 | ALDH1A1 (0.48) | ALDH1A1ATMTSHRHPGDCA2 | |
| SCHEMBL27780513 | 0.89 | NAAA (0.50) | ALDH1A1TSHRLMNAHCAR2NAAA | |
| SCHEMBL27911796 | 0.89 | ALDH1A1 (0.45) | ALDH1A1ATMTSHRHPGDCA2 | |
| SCHEMBL27780734 | 0.89 | NAAA (0.50) | ALDH1A1TSHRLMNAHCAR2NAAA | |
| SCHEMBL5200822 | 0.88 | CA2 (0.41) | ALDH1A1ATMTSHRHPGDCA2 | |
| SCHEMBL28743152 | 0.88 | ACHE (0.49) | ALDH1A1TSHRLMNANAAAEPHX1 | |
| SCHEMBL6264997 | 0.87 | ZDHHC7 (0.43) | ALDH1A1CA2NAAAEPHX1 | |
| SCHEMBL27625744 | 0.86 | ALDH1A1 (0.42) | ALDH1A1ATMTSHRHPGDCA2 | |
| SCHEMBL5202946 | 0.86 | ALDH1A1 (0.50) | ALDH1A1ATMTSHRHPGDCA2 | |
| SCHEMBL29119069 | 0.85 | FAAH (0.44) | ALDH1A1TSHRESR1HCAR2NAAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1973006-B | Single-component system based on co-reactive latex, preparation method and use in the field of formol-free coatings | ARKEMA | 2010-11-10 | — | — | CN | claimed |
| CN-1973006-A | Single-component system based on co-reactive latex, preparation method and use in the field of formol-free coatings | ARKEMA (FR) | 2007-05-30 | — | — | CN | claimed |
| EP-1778804-A1 | SINGLE-COMPONENT SYSTEM BASED ON CO-REACTIVE LATEX, PREPARATION METHOD AND USE IN THE FIELD OF FORMOL-FREE COATINGS | Arkema France (FR) | 2007-05-02 | — | — | EP | claimed |
| WO-2006010804-A1 | SINGLE-COMPONENT SYSTEM BASED ON CO-REACTIVE LATEX, PREPARATION METHOD AND USE IN THE FIELD OF FORMOL-FREE COATINGS | ARKEMA FRANCE (FR) | 2006-02-02 | — | — | WO | claimed |
| US-6867218-B2 | Compounds, their preparation and use | NOVO NORDISK A/S (DK) | 2005-03-15 | — | — | US | disclosed |
| US-20030195200-A1 | Compounds, their preparation and use | VTVX HOLDINGS II LLC | 2003-10-16 | — | — | US | disclosed |
| US-6555577-B1 | For treatment and/or prevention of conditions mediated by the Peroxisome Proliferator-Activated Receptors (PPAR), such as diabetes and/or obesity; 3-(4-(3-Biphenyl-4-yl-but-2-enyloxy)-phenyl)-2-butoxy-propionic acid for example | NOVO NORDISK A/S (DE) | 2003-04-29 | — | — | US | disclosed |
| EP-1254101-A1 | PROPIONIC ACID DERIVATIVES AND THEIR USE IN THE TREATMENT OF DIABETES AND OBESITY | Novo Nordisk A/S (DK) | 2002-11-06 | — | — | EP | disclosed |
| WO-2001055085-A1 | PROPIONIC ACID DERIVATIVES AND THEIR USE IN THE TREATMENT OF DIABETES AND OBESITY | NOVO NORDISK A/S (DK) | 2001-08-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030195200-A1 | Compounds, their preparation and use | PPARG, PPARA, PPARD | ALDH1A1 257/4885ATM 3447/4885TSHR 659/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.